Since AML-M5 was easy differentiated from APL by relative high value of CD64 ratio, we therefore drew ROC curves to evaluate the diagnosis performance of the MFI ratio of the CD64 marker alone to differentiate APL from non-APL/M5 patients. This evidence concerns the gene FCGR1A and acute myeloid leukemia.